Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes  by Schrier, Robert W. et al.
Kidney International, Vol. 61 (2002), pp. 1086–1097
Effects of aggressive blood pressure control in normotensive
type 2 diabetic patients on albuminuria, retinopathy
and strokes
ROBERT W. SCHRIER, RAYMOND O. ESTACIO, ANNE ESLER, and PHILIP MEHLER
Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Health Sciences Center,
and Department of Internal Medicine, Denver Health and the University of Colorado Health Sciences Center,
Denver, Colorado, USA
(128/75 mm Hg) BP control in normotensive type 2 diabeticEffects of aggressive blood pressure control in normotensive
patients: (1) slowed the progression to incipient and overt dia-type 2 diabetic patients on albuminuria, retinopathy and
betic nephropathy; (2) decreased the progression of diabeticstrokes.
retinopathy; and (3) diminished the incidence of stroke.Background. Although several important studies have been
performed in hypertensive type 2 diabetic patients, it is not
known whether lowering blood pressure in normotensive
(BP 140/90 mm Hg) patients offers any beneficial results on
Diabetes mellitus is the most common cause of end-vascular complications. The current study evaluated the effect
stage renal disease (ESRD) [1, 2], adult blindness [3, 4]of intensive versus moderate diastolic blood pressure (DBP)
control on diabetic vascular complications in 480 normotensive and amputations in the United States and is a major risk
type 2 diabetic patients. factor for heart attacks and strokes [5]. Approximately
Methods. The current study was a prospective, randomized 90% of diabetes is classified as type 2 or non-insulincontrolled trial in normotensive type 2 diabetic subjects. The
dependent mellitus. Since hypertension is a common ac-subjects were randomized to intensive (10 mm Hg below the
companiment of type 2 diabetes in adults, there havebaseline DBP) versus moderate (80 to 89 mm Hg) DBP control.
Patients in the moderate therapy group were given placebo, been several recent studies examining the role of differ-
while the patients randomized to intensive therapy received ent antihypertensive agents in lowering blood pressure
either nisoldipine or enalapril in a blinded manner as the initial in hypertensive type 2 diabetic patients. A beneficialantihypertensive medication. The primary end point evaluated
effect of diuretics [6], beta blockers [7], angiotensin-con-was the change in creatinine clearance with the secondary
verting enzyme (ACE) inhibitors [8] and calcium chan-endpoints consisting of change in urinary albumin excretion,
progression of retinopathy and neuropathy and the incidence nel blockers (CCBs) [9, 10] in lowering blood pressure
of cardiovascular disease. and decreasing vascular complications in type 2 diabetic
Results. The mean follow-up was 5.3 years. Mean BP in the patients have been demonstrated. In most of these stud-intensive group was 128  0.8/75  0.3 mm Hg versus 137 
ies however these agents have been compared against0.7/81  0.3 mm Hg in the moderate group, P  0.0001. Al-
placebo, therefore significant differences in blood pres-though no difference was demonstrated in creatinine clearance
(P 0.43), a lower percentage of patients in the intensive group sure have occurred. The Appropriate Blood Pressure
progressed from normoalbuminuria to microalbuminuria (P Control in Diabetes (ABCD) study in hypertensive pa-
0.012) and microalbuminuria to overt albuminuria (P 0.028). tients [11], and the United Kingdom Prospective Diabe-The intensive BP control group also demonstrated less progres-
tes Study (UKPDS) have compared different levels ofsion of diabetic retinopathy (P  0.019) and a lower incidence
blood pressure control in hypertensive type 2 diabeticof strokes (P  0.03). The results were the same whether
enalapril or nisoldipine was used as the initial antihypertensive patients. In the UKPDS study the less tight blood pres-
agent. sure goal was 180/105 mm Hg and the tight blood
Conclusion. Over a five-year follow-up period, intensive pressure goal was 150/85 mm Hg [7], whereas in the
hypertensive ABCD study, the diastolic blood pressure
goals were 80 to 89 mm Hg (moderate) and75 mm HgKey words: type 2 diabetes, hypertensive therapy, microvascular com-
plications. (intensive).
While these above studies have added a great deal ofReceived for publication June 6, 2001
understanding about the effects of treating hypertensionand in revised form October 9, 2001
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Fig. 1. Design and patient follow up rates for the ABCD Trial.
lowering in blood pressure in normotensive (140/90 the primary antihypertensive medication. The patients
randomized to the moderate therapy group were givenmm Hg) type 2 diabetic patients is beneficial. To address
this important question the normotensive ABCD study placebo, but were also randomized to receive nisoldipine
or enalapril if they subsequently became hypertensiveprospectively randomized 480 type 2 diabetic patients to
moderate (diastolic 80 to 89 mm Hg, placebo group) (systolic BP160 and/or diastolic BP90 mm Hg). The
primary objective of the study was to determine theversus intensive (diastolic decrease of 10 mm Hg, inten-
sive group) blood pressure goals. effect of moderate versus intensive blood pressure con-
trol on the change in creatinine clearance. The primary
hypothesis of the study was that intensive blood pressure
METHODS control would prevent the development and/or progres-
Design sion of diabetic nephropathy.
The Appropriate Blood Pressure Control in Diabetes
Participants(ABCD) trial was a prospective, controlled, randomized
trial based in Denver, Colorado. The Colorado Multiple Subjects in the ABCD study were between the ages
of 40 and 74 years at the time of recruitment and wereInstitutional Review Board approved the study prior to
its initiation and an informed consent was obtained from identified from Diagnosis Related Group, pharmacy and
billing lists from participating healthcare systems in theall study subjects prior to their participation. The normo-
tensive ABCD study (480 participants) evaluated the Denver metropolitan area. All patients in the ABCD
study were diagnosed with type 2 diabetes according toeffects of intensive versus moderate blood pressure con-
trol on diabetic vascular complications (Fig. 1). The the criteria based upon the World Health Organization
report of 1985 [13]. All enrolled normotensive subjectsABCD Trial design has been described previously [12].
Four hundred and eighty normotensive type 2 diabetic had a diastolic blood pressure between 80 and 89 mm Hg
and were not receiving antihypertensive medications atsubjects were randomized in the ABCD Trial to moder-
ate versus intensive antihypertensive treatment. Within the randomization visit. Twenty-six patients with systolic
hypertension (diastolic BP 80 to 89 mm Hg and systolicthe intensive treatment groups, patients were further
randomized to receive either nisoldipine or enalapril as BP 160 mm Hg) were enrolled in the study during the
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first year of recruitment but none thereafter because of of the patient except the blood pressure control (for
example, blood glucose, lipids, smoking, etc.)the 1992 publication of the Systolic Hypertension in the
Elderly Program (SHEP) results [6]. Patients were ex- During the follow-up period, the patients’ primary
care physicians managed blood glucose control, bloodcluded if they had a known allergy to dihydropyridines
or ACE inhibitors, a myocardial infarction or cerebral lipids and anti-smoking interventions.
vascular accident within the previous six months, coro-
Study end pointsnary artery bypass surgery within the previous three
months, unstable angina pectoris within the previous six The primary endpoint was the effect of intensive ver-
sus moderate blood pressure control on the change inmonths, Class III or IV New York Heart Association
classification of congestive heart failure, demonstrated 24-hour creatinine clearance, which was assessed every
six months. Secondary endpoints included the effect ofan absolute need for ACE inhibitors or calcium channel
blockers, were receiving hemo- or peritoneal dialysis intensive versus moderate blood pressure control on car-
diovascular events, retinopathy as determined by stereo-and/or had a serum creatinine greater than 3 mg/dL.
scopic retinal photographs [14], clinical neuropathy [15],
Randomization and study therapy and urinary albumin excretion [16].
During the 7 to 11 week single-blind placebo run-in
Renal end pointsperiods, all baseline studies were performed. After the
placebo run-in, the mean baseline diastolic blood pres- Glomerular filtration rates (GFR) were estimated
from 24-hour creatinine clearances standardized forsure was determined at two separate visits for each pa-
tient. Subjects with a mean baseline diastolic blood pres- body surface area obtained at baseline then every six
months during the course of the study. Given the nearsure between 80 and 89 mm Hg were eligible for the study
and placed in the normotensive study. Randomization normal creatinine clearances for the present group of
type 2 diabetic patients, the effect of tubular secretionoccurred using permuted block randomization within
strata. Patients were randomized into two treatment of creatinine would be expected to be minimal. More-
over, as reported earlier, iothalamate clearances in 200arms consisting of an intensive treatment with a diastolic
blood pressure goal of 10 mm Hg below the randomiza- type 2 diabetic patients in the ABCD study correlated
closely with creatinine clearance (abstract; Savage et al,tion diastolic blood pressure and moderate (placebo)
treatment with a diastolic blood pressure goal between American Society of Nephrology Meeting 1993). Urinary
albumin excretion (UAE) was measured using radioim-80 to 89 mm Hg. The intensive therapy patients were
randomized to either nisoldipine 10 mg/day titrated to munoassay techniques (RAI) from 24-hour and over-
night collections at baseline and every two months there-20, 40 and then 60 mg/day (plus placebo for enalapril)
or enalapril 5 mg/day titrated to 10, 20 and then 40 mg/ after following randomization. At baseline, the stage of
UAE (normoalbuminuria, microalbuminuria and overtday (plus placebo for nisoldipine) as the initial medica-
tion. If the single study medication alone did not achieve albuminuria) was based on one 24-hour collection and
two overnight collections. Normoalbuminuria was de-the target blood pressure, then open-labeled antihyper-
tensive medications were added in a step-wise fashion fined as less than 20 g/min (30 mg/24 h), microalbumin-
uria as 20 to 200 g/min (30 to 300 mg/24 h), and overtuntil the target blood pressure was achieved. Open-labeled
antihypertensive medications included metoprolol and albuminuria as 200 g/min (300 mg/24 h). The stage
of microalbuminuria is considered incipient diabetic ne-hydrochlorothiazide. Additional antihypertensive medi-
cations were added at the discretion of the medical direc- phropathy and overt albuminuria is considered estab-
lished diabetic nephropathy. Urinary albumin, sodiumtor, but did not include a calcium channel blocker or
ACE inhibitor. If a patient randomized to moderate and potassium excretion, and creatinine clearance were
measured by the Renal Research Laboratory at the Uni-therapy became hypertensive (systolic blood pressure
160 and/or a diastolic blood pressure 90 mm Hg on versity of Colorado Health Sciences Center.
2 consecutive visits), they were given either nisoldipine
Retinopathy end pointsor enalapril according to randomization at entry into the
study with the goal of maintaining the systolic blood Retinopathy was staged using the Modified Airlie
House Classification of Diabetic Retinopathy as waspressure 160 mm Hg and the diastolic blood pressure
between 80 and 90 mm Hg. Blood pressure recordings adapted for the Diabetes Control and Complications
Trial by the Fundus Photograph Reading Center at thewere obtained at peak drug levels and were an average
of three seated readings obtained at each visit. Study University of Wisconsin. Seven-field stereoscopic fundus
photographs were taken on-site at baseline then at yearnurses were blinded to the use of enalapril versus nisol-
dipine, but could not be blinded with respect to intensive 2 and 5 by a technician trained by the Reading Center.
All retinal films were interpreted and graded by theversus moderate blood pressure control. The patient’s
primary care physicians were responsible for the care Fundus Photograph Reading Center without knowledge
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of the treatment arm. The graders used the protocol nicity and the presence of diabetic complications (overt
albuminuria, microalbuminuria, retinopathy, neuropa-of the Early Treatment Diabetic Retinopathy Study
(ETDRS) [14]. The overall level of severity of retinopa- thy and cardiovascular disease)].
T tests at each time point and a general linear mixedthy was determined for each patient according to the
ETDRS interim scale [17], in which a scale of 23 steps model were used when comparing change in systolic and
diastolic blood pressure (SBP and DBP) between theis used to represent the overall extent of retinopathy
in both eyes. The progression of clinically important intensive and moderate therapy groups as well as be-
tween the nisoldipine and enalapril groups. Similar anal-retinopathy is defined as a change of at least two steps
from baseline measurements. yses were undertaken for glycosylated hemoglobin and
total cholesterol. A general linear mixed model was also
Diabetic neuropathy used when evaluating the effects of blood pressure con-
trol (intensive vs. moderate) over time on measures ofThe presence and progression of diabetic neuropathy
was assessed according to the criteria established by renal function [creatinine clearance and log urinary albu-
min excretion (log UAE)]. The general linear model isDyck [18]. This included neurological symptoms score,
neurological disability score, autonomic nervous system ideally suited for these types of unbalanced repeated
measures data. Log (UAE) was used instead of UAEtesting with heart rate response to deep breathing, and
quantitative sensory examination performed at baseline because of the non-Gaussian nature of the UAE values
as well as the extremely large variance seen in the UAEthen at year 2 and 5. Details of the exam have been
discussed previously [12]. values. To further enhance the understanding of the lon-
gitudinal effects of blood pressure control on renal func-
Cardiovascular disease tion, t tests were carried out at each time point. These
tests are especially helpful in describing interactive ef-An independent Endpoint Committee, whose mem-
bers were blinded to the study intervention arms, re- fects between blood pressure control and time.
viewed all cardiovascular events. Cardiovascular out- The progression of retinopathy and neuropathy were
comes were defined as (1) death due to cardiovascular analyzed using Chi-square tests. The incidence of cardio-
events (sudden death, progressive heart failure, fatal myo- vascular events was also analyzed utilizing a Chi-square
cardial infarction, fatal arrhythmias, cerebral vascular test. In addition, the progression of albuminuria over
accidents and ruptured aortic aneurysm); (2) non-fatal time was examined using Kaplan-Meier survival curves
myocardial infarction; (3) non-fatal cerebral vascular ac- and log-rank tests.
cident; (4) heart failure requiring hospital admission;
and (5) pulmonary infarction. The End Point Committee
RESULTSreviewed all hospital admissions that appeared to be
There were no significant differences in the baselinerelated to a cardiovascular event.
characteristics and prevalence of clinical complications
Statistics when comparing those patients randomized to intensive
and moderate treatment groups (Table 1) and enalaprilThe Statistical Analysis Software (SAS) system was
and nisoldipine groups (Table 2). There also was noused for all statistical analyses. Data are summarized as
difference in patient characteristics between those re-mean  standard error for continuous endpoints and
ceiving active drug treatment (Table 3). The baselinepercentage of relevant population for categorical vari-
characteristics including important interrelationships withables. Two different statistical procedures were utilized
diabetic complications of the ABCD Trial populationwhen examining differences in baseline characteristics
have been reported in previous publications [19–26].or the presence of diabetic complications between the
intensive and moderate therapy groups, and between
Blood pressurethe original randomized drugs (nisoldipine or enalapril).
During the course of the study, a blood pressure sepa-When the baseline characteristic was continuous [age,
ration was achieved between the intensive and moderateduration of diabetes, body mass index (BMI), glycosy-
therapy groups within the first 6 to 12 months and waslated hemoglobin, systolic blood pressure (SBP), dia-
maintained for the remainder of the follow-up periodstolic blood pressure (DBP) and years of education] a
(Fig. 2). Thus, the mean blood pressure for the last 4two-sample t test was used. When any of these baseline
years of follow-up was 128  0.8/75  0.3 mm Hg forcharacteristics were clearly non-Gaussian distributed,
the intensive antihypertensive therapy group and 137 nonparametric analyses (that is, Wilcoxon’s Rank Sum
0.7/81  0.3 mm Hg for the moderate antihypertensiveTest) or parametric analyses on suitably transformed
therapy group, P  0.0001, were utilized as the bloodvariables were performed. Chi-square analyses were un-
pressure achieved during the study. There were no differ-dertaken when the baseline characteristic or complica-
tion was categorical [gender, smoking status, race/eth- ences in systolic and diastolic blood pressures during the
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Table 2. Patient baseline characteristics and complications atTable 1. Patient baseline characteristics and complications
at baseline according to intensive and moderate blood baseline according to enalapril and nisoldipine assignment
pressure therapy
Enalapril Nisoldipine
Characteristic (N  246) (N  234)Intensive therapy Moderate therapy
Characteristic (N  237) (N  243)
Age at randomization 59.40.5 59.10.5
% Male 53.3 56.0Age 58.50.6 59.60.5
% Male 53 56 Diabetes duration years 8.80.4 9.20.5
Glycosylated hemoglobin % 11.50.2 11.60.2Diabetes duration years 8.80.5 9.20.5
Glycosylated hemoglobin % 11.50.2 11.60.2 Body mass index kg/m2 31.50.4 31.50.4
% Smoking statusBody mass index kg/m2 31.50.4 31.50.4
% Smoking status Past 45.5 46.2
Current 12.6 13.7Past 49 42
Current 13 13 Systolic blood pressure at
randomization mm Hg 137.40.9 135.40.8Systolic blood pressure at
randomization mm Hg 135.60.8 137.20.9 Diastolic blood pressure at
randomization mm Hg 84.50.2 84.30.2Diastolic blood pressure at
randomization mm Hg 84.40.2 84.40.2 Years of education 13.40.2 13.50.2
Race and ethnicityYears of education 13.70.2 13.20.2
Race and ethnicity Non-Hispanic white 74.0 72.7
African American 8.1 6.0Non-Hispanic white 75 72
African-American 7 7 Hispanics 15.5 19
ComplicationsHispanics 16 18
Complications % with overt albuminuria 11 11
% with microalbuminuria 23 23% with overt albuminuria 9.3 12
% with microalbuminuria 21 25 % with diabetic retinopathy 48.7 50.7
% with diabetic neuropathy 43.7 43.5% with diabetic retinopathy 50 50
% with diabetic neuropathy 42 45 % with CAD 23 25
% with CHF 1.6 2.1% with CAD 21 27
% with CHF 2 2 % with CVA 3.3 3.0
% with CVA 3 4 Data are SE or percent. Patents randomized to the moderate therapy group
were initially given placebo.Data are presented as means  SE. or percent. Overt albuminuria is defined
as urinary albumin excretion 200 gm/min (300 mg/day). Microalbuminuria
is defined as urinary albumin excretion between 20–200 gm/min (30–300 mg/
day). CVD (cardiovascular disease) is defined as those with a previous history
of coronary artery disease, cerebral vascular accident and/or congestive heart
failure; angina by Rose Questionnaire; an abnormal ankle-brachial index; and/or
left ventricular hypertrophy by electrocardiogram.
Table 3. Characteristics of patients given a drug (intensive therapy,
N  237; moderate therapy, N  117) using values closest to the
first time the drug was given
follow-up period when comparing patients randomized
Enalapril Nisoldipine
to nisoldipine, 132.1  0.7/78.0  0.4 mm Hg, versus Characteristic (N  181) (N  173) P value
enalapril, 132.4  0.9/78.0  0.4 mm Hg, P  0.8. By
Age at randomization 59.60.6 58.90.6 0.47
the end of the study, 117 (48%) of patients initially ran- % Male 50.3 55.5 0.33
Diabetes duration years 9.40.5 9.60.6 0.71domized to the moderate therapy group (placebo) devel-
Glycosylated hemoglobin % 11.60.3 11.30.2 0.51oped hypertension (DBP 90 mm Hg and/or SBP 160
Body mass index kg/m2 31.40.5 31.60.5 0.76
mm Hg) requiring use of antihypertensive medications % Smoking status
Past 45.3 49.7 0.28to lower their diastolic blood pressure between the 80
Current 10.5 13.9and 90 mm Hg range or their systolic blood pressure
Systolic blood pressure at
below 160 mm Hg (Fig. 1). These patients in the moder- randomization mm Hg 141.71.2 137.61.0 0.01
Diastolic blood pressure atate therapy group were then given nisoldipine or enala-
randomization mm Hg 85.90.3 85.50.3 0.35pril rather than placebo according to their initial random-
Years of education 13.50.2 13.60.2 0.90
ization scheme. Race and ethnicity 0.18
Non-Hispanic white 74.0 74.0No significant difference was noted between the inten-
African American 9.4 4.6sive and moderate groups with regard to allocation of
Hispanics 14.4 19.1
metoprolol (18% in the intensive and 15% in the moder- Complications
% with overt albuminuria 13.9 (N  25) 12.1 0.89ate blood pressure group, P 0.33) and hydrochlorothia-
% with microalbuminuria 21.7 (N  39) 22.0 0.89zide (37% in the intensive and 30% in the moderate
% with diabetic
blood pressure group, P 0.15) as additional antihyper- retinopathy 49.1 (N  84) 53.7 0.67
% with diabetictensive medication. Within the intensive and moderate
neuropathy 43.9 (N  79) 46.8 0.48therapy groups, there was no significant difference be-
% with CAD 21.6 (N  39) 22 0.92
tween the major antihypertensive medications used (ena- % with CHF 2.2 2.3 0.99
% with CVA 2.2 4.1 0.37lapril, nisoldipine and hydrochlorothiazide) except for
Data are  SE or percent.the patients randomized to enalapril in which more pa-
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Fig. 3. Mean total cholesterol (normal range 130 to 200 mg/dL) and
glycosylated hemoglobin (normal range 4.2 to 7.0%) values  standard
errors over 5-years for the intensive (solid line) versus moderate (dashed
line) therapy (A), and nisoldipine (solid line) versus enalapril (dashed
line) therapy (B). T tests at each time interval reveal no significant
difference between the therapies.
37%, P  0.44; enalapril, 36%; nisoldipine, 42%; P 
0.24), aspirin (intensive, 52% vs. moderate, 55%, P 
0.42; enalapril, 54% nisoldipine, 53%, P  0.74) and
insulin (intensive, 65% vs. moderate, 65%, P  0.92;Fig. 2. Mean systolic (A) and diastolic (B) blood pressures  standard
errors according to intensive (solid line) versus moderate (dashed line) enalapril, 63%; nisoldipine, 68%; P 0.30) between the
therapy throughout 5 years. T tests at each time interval revealed a intervention groups.significant and persistent blood pressure separation occurred after 6
months between the two interventions, P  0.0001.
Nephropathy
Repeated measures analyses demonstrated that the
clearance values throughout the five-year follow-up pe-tients randomized to enalapril were placed on metopro-
riod were not significantly different between the inten-lol (22%) then those randomized to nisoldipine (11%,
sive versus moderate therapy groups (P  0.43; Fig. 4).P 0.002). During the 5.3 years of follow-up, the patients
Furthermore, there was also no difference in the changewere on their initial randomized study medication (nisol-
in creatinine clearance between those patients random-dipine or enalapril) an average of 70% of the study
ized to nisoldipine and enalapril (Fig. 4). Virtually theperiod.
entire decline in creatinine clearance occurred within the
first year of the study. The change in serum creatinineOther variables
was 0.062  0.29 for the intensive versus 0.044  0.35Although blood glucose and lipid control were subop-
for the moderate blood pressure group at five years (Ptimal during the study, there was no difference in glycosy-
0.61).lated hemoglobin at baseline (intensive, 11.5  0.2%
The creatinine clearance values for patients startingversus moderate, 11.6 0.1%, P 0.81; enalapril, 11.4
with normoalbuminuria (N  319) and microalbumin-0.2% vs. nisoldipine, 11.7  0.1%, P  0.12; normal 4.2
uria (N  109) were no different for the intensive andto 7.0%) and total cholesterol (intensive, 216.4  3.1
moderate therapy groups (Fig. 5). Similar analyses com-mg/dL vs. moderate, 213.6 2.6 mg/dL, P 0.48; enala-
paring the use of nisoldipine and enalapril in patientspril, 214.3 2.6 mg/dL vs. nisoldipine, 215.7 3.1mg/dL,
with normoalbuminuria and microalbuminuria at base-P  0.73; normal 130 to 200 mg/dL) and during the
line revealed no significant difference (data not shown).follow-up period between the intervention groups (Fig. 3).
However, patients with overt albuminuria at baselineDuring the study, there was no difference in the use
of lipid lowering agents (intensive, 41% vs. moderate, exhibited a significant fall in creatinine clearance over
Schrier et al: BP control in normotensive diabetes1092
Fig. 4. Mean creatinine clearances  standard errors according to (A)
Fig. 5. Mean creatinine clearances  standard errors according to in-intensive (solid line) versus moderate (dashed line) blood pressure
tensive (solid line) versus moderate (dashed line) therapy for patientscontrol and (B) nisoldipine (solid line) versus enalapril (dashed line).
with normoalbuminuria (A) and microalbuminuria (B) at baseline.
the five year follow-up (intensive therapy: 81.8  7.1 of intensive blood pressure control to stabilize urinary
mL/min/1.73 m2 to 51.5  11.9 mL/min/1.73 m2, P  albumin excretion in the normo- and microalbuminuric
0.027; and moderate therapy: 76.8  5.5 mL/min/1.73 m2 groups. Subgroup analyses revealed a significant interac-
to 56.6  8.1 mL/min/1.73 m2, P  0.04); there was no tion between time and intervention (intensive vs. moder-
significant difference between the intensive and moder- ate) for those patients starting with normoalbuminuria
ate treatment groups. A similar analysis comparing nisol- (P 0.0003) or microalbuminuria (P 0.009) at baseline
dipine versus enalapril revealed no difference between but not in those with overt albuminuria at baseline (P 
the interventions (P  0.62). 0.21). For patients starting with overt albuminuria, there
Log UAE values were reported because of the large was no significant change in the log UAE when compared
variance observed in the absolute values for UAE. Re- to baseline (intensive, change from 6.3  0.2 to 6.4 
peated measures analyses demonstrated a statistically 0.5, P  0.78; moderate, change from 6.4  0.3 to 6.2 
significant interaction between time and intervention 0.5, P  0.72; enalapril, change from 6.4  0.2 to
with the change in log UAE (0.36 1.41 for the intensive 5.8  0.4, P  0.28; and nisoldipine, change from 6.3 
blood pressure group versus 0.66 1.47 for the moderate 0.3 to 6.5 0.4, P 0.71). However, the statistical power
blood pressure group at 5 years, P  0.0001); however, in the overt albuminuria group was limited. During the
there was no difference between the use of nisoldipine study, no patient converted back from overt albuminuria
to microalbuminuria. However, 23 patients revertedand enalapril (P 0.98). Figure 6 demonstrates the effect
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Fig. 7. Kaplan-Meier curves demonstrating progression from normoal-
buminuria to microalbuminuria (A; P  0.04) and from microalbumin-Fig. 6. Log urinary albumin excretion (UAE) for intensive (solid line)
uria to overt albuminuria (B; P  0.02) in patients on (solid line)and moderate (dashed line) blood pressure control groups: (A) normoal-
intensive versus (dashed line) moderate therapy.buminuria at baseline; (B) microalbuminuria at baseline. *T test per-
formed at various time intervals revealed a P value 0.05.
from microalbuminuria to normoalbuminuria, 15 pa- Retinopathy
tients in the intensive group and 8 patients in the moder-
Over a five-year follow-up period, there was less pro-ate group (P  0.03).
gression of diabetic retinopathy at two years (13 vs. 21%,A significantly lower percentage of patients pro-
P  0.046) and five years (34 vs. 46%, P  0.019) ingressed from normoalbuminuria to microalbuminuria
patients randomized to the intensive therapy group.(P  0.012) and microalbuminuria to overt albuminuria
There was no statistically significant difference between(P  0.028) in the intensive therapy group when com-
those patients randomized to nisoldipine versus enalaprilpared to the moderate therapy group. Figure 7 displays
in the intensive group (at 5 years, 38 vs. 30%, respec-the progression from normoalbuminuria to microalbu-
tively, P 0.29). When evaluating the number of patientsminuria and from microalbuminuria to overt albumin-
developing retinopathy from no retinopathy at baselineuria within each intervention over the course of the
to five years, 39% of patients in the intensive therapystudy. The progression curves differ significantly be-
group versus 42% in the moderate therapy group devel-tween the intensive and moderate therapy groups for
oped retinopathy. With regard to the development ofthe development of microalbuminuria (P  0.04) and
proliferative retinopathy, 0% of patients in the intensiveovert albuminuria (P  0.02). In addition, change in log
therapy group versus 3.9% developed proliferative reti-UAE from baseline differed significantly between the
nopathy.intensive and moderate therapy groups at years 2, 3 and
4 years (P values from 0.0006 to 0.05). Similar compari-
Neuropathysons of progression rates between those patients ran-
During the follow-up period, 38% of patients random-domized to nisoldipine and enalapril were not signifi-
ized to intensive therapy versus 38% of patients random-cantly different (baseline normoalbuminuria, P  0.63;
baseline microalbuminuria, P  0.85). ized to moderate therapy had progression of neuropathy
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Table 4. Cardiovascular outcomes according to intervention: Intensive versus moderate and nisoldipine versus enalapril
Intensive therapy Moderate therapy
CV Outcome N  237 (%) N  243 (%) OR (95% CI) P value
Myocardial infarction 19 (8.0) 15 (6.2) 0.75 (0.37, 1.52) 0.43
CVA 4 (1.7) 13 (5.4) 3.29 (1.06, 10.25) 0.03
CHF 12 (5.1) 11 (4.5) 0.89 (0.38, 2.06) 0.78
CV death 13 (5.4) 9 (3.7) 0.66 (0.28, 1.58) 0.35
Death 18 (7.6) 20 (8.2) 1.1 (0.56, 2.12) 0.80
Nisoldipine Enalapril
N  234 (%) N  246 (%)
Myocardial Infarction 18 (7.7) 16 (6.5) 1.20 (0.60, 2.41) 0.61
CVA 11 (4.7) 6 (2.4) 1.97 (0.72, 5.42) 0.18
CHF 11 (4.7) 12 (4.9) 0.96 (0.42, 2.22) 0.93
CV death 8 (3.4) 14 (5.7) 0.59 (0.24, 1.43) 0.23
Death 19 (8.1) 19 (7.7) 1.1 (0.54, 2.05) 0.87
Abbreviations are: CVA, cerebral vascular accident; CHF, congestive heart failure; CV, cardiovascular
at five years (P  0.87). During the follow-up period, type 2 diabetic patients with a primary purpose of exam-
ining the effect of intensive lowering of blood pressure36% of patients randomized to nisoldipine versus 40%
of patients randomized to enalapril had progression of on diabetic complications. Specifically, our question was:
in type 2 diabetic patients with baseline blood pres-neuropathy at five years (P  0.38).
sures 140/90 mm Hg is there any beneficial effect of
Cardiovascular disease further lowering of blood pressure with antihypertensive
agents, and if so to what level? The present prospectiveTable 4 shows the number of patients with new cardio-
randomized ABCD study in 480 normotensive type 2vascular events throughout the follow-up period. Pa-
diabetic patients addressed this important question.tients randomized to the intensive therapy group had a
It is well accepted that renal function deteriorates withsignificantly lower incidence of cerebral vascular acci-
age [27]. Yet in the current ABCD study in elderly typedents when compared to the moderate therapy group
2 diabetic patients creatinine clearance did not decrease(1.7 vs. 5.4%, P  0.03). No significant difference in
over a four-year period after the initial hemodynamiccardiovascular events or deaths occurred between the
effect of blood pressure control. Thus, it can be arguednisoldipine and enalapril groups. Similar analyses per-
that the failure to control blood pressure in the elderlyformed only on patients receiving active drug (enalapril,
is the reason for the decline in renal function rather thanN  168; nisoldipine N  163) also revealed no statisti-
attributing it to the aging process. In support of thiscally significant difference in the incidence of cardiovas-
interpretation is the recent publication emphasizing thecular events, P  0.6).
poor blood pressure control in the elderly in this countryAnalyses excluding the 26 patients with isolated hyper-
[28].tension (SBP160 mm Hg and DBP90 mm Hg) were
Ravid et al demonstrated, in normotensive type 2 dia-performed and revealed no change in the outcome find-
betic patients with normo- or microalbuminuria receiv-ings and interpretation. Since a higher percentage of
ing placebo, that there was a significant fall in creatininepatients utilized metoprolol in the enalapril treatment
clearance over a five to six follow-up period, which couldgroup, additional analyses were performed excluding
be avoided with ACE inhibitor treatment [29, 30]. Asthe patients utilizing metoprolol. When the metoprolol
discussed, in the present study creatinine clearance wastreated patients were removed the results were not sig-
stabilized with both intensive and moderate blood pres-nificantly different.
sure control less than 140/90 mm Hg. In this regard, the
NHANES study (1991–1994) reported only 17 percent
DISCUSSION of diabetic patients had blood pressures controlled below
In recent years there have been several important 140/90 mm Hg [31]. As previously suggested [32], the
studies in hypertensive type 2 diabetic patients examin- present ABCD study observations indicate that stabiliza-
ing the effect of different levels of blood pressure control tion of renal function in normotensive type 2 diabetic
and different antihypertensive agents on diabetic compli- patients is best achieved at the normo- or microalbumi-
nuric stage with blood pressure control 140/90 mmcations [6–11]. In general the results of these studies
support the beneficial effect of intensive blood pressure Hg. However, in the patients who had overt albuminuria
at study entry, renal function declined significantlylowering in diabetic subjects. However, there has not
been a prospective randomized study in normotensive throughout the present study, averaging approximately
Schrier et al: BP control in normotensive diabetes 1095
5 mL/min annual decline in creatinine clearance, inde- to decrease the progression of retinopathy. This effect
on the progression of retinopathy was significant whetherpendent of intensive or moderate blood pressure control
or whether the initial antihypertensive therapy was with analyzed by intention to treat or time on active drug.
The results of the present study lend further supportenalapril or nisoldipine. These results are similar to a
study reported by Parving et al in which antihypertensive for the United Kingdom Prospective Diabetes Study
(UKPDS), which demonstrated that over a nine yeartherapy resulted in the slower decline in of glomerular
filtration rate (3 mL/min/year) when compared to a pla- follow-up tighter blood pressure control led to a decrease
in the need for photocoagulation in a hypertensive typecebo (11 mL/min/year) [33]. At a rate of decline in glo-
merular filtration rate between 3 and 5 mL/min/year, 2 diabetic population [7].
While stability of renal function and slowing of pro-renal replacement therapy in the diabetic patients should
not be necessary until their late seventies. This conclu- gression of retinopathy with intensive blood pressure
control occurred, there was still worsening of retinopathysion has important implications since diabetic patients
now constitute 45% of new patients receiving renal re- and also neuropathy in these normotensive type 2 dia-
betic subjects in spite of intensive blood pressure control.placement therapy [34].
In the present study, there were significant and clini- In addition, there was no evidence that the use of nisol-
dipine versus enalapril as the initial antihypertensivecally important differences with regard to the progres-
sion of urinary albumin excretion, diabetic retinopathy agent was advantageous with regard to either the pro-
gression of neuropathy or retinopathy. The suboptimaland the incidence of stroke between the moderate and
intensive blood pressure control groups, whether ana- blood glucose and lipid control over the follow-up period
of this ABCD study are potential factors in the progres-lyzed as intention to treat or time on active drug. With
respect to urinary albumin excretion, there is general sion of the retinopathy and neuropathy. The recent re-
sults of the UKPDS provide support for the concept thatagreement that it is an important surrogate of diabetic
nephropathy progression. In this regard, urinary albumin blood glucose control results in slowing the progression
of microangiopathy in type 2 diabetes [41].excretion may even be a stronger predictor of cardiovas-
cular outcomes [35]. In the present study, the more ag- Of all the complications associated with diabetes, neu-
ropathy is the most poorly defined, but may be the mostgressive blood pressure control (mean 128/75 mm Hg)
compared to the moderate control (mean 137/81 mm Hg) prevalent. Cross sectional studies suggest a possible rela-
tionship between hypertension and the presence of neu-decreased the rate of progression of normoalbuminuria
to microalbuminuria (incipient nephropathy) and of ropathy [42]. Interventional studies demonstrating a ben-
efit with regard to progression of neuropathy have onlymicroalbuminuria to overt albuminuria (diabetic ne-
phropathy; both P  0.03). involved glycemic control [41], aldose reductase inhibi-
tors [43] and alpha-lipoic acid [44], but not antihyperten-Most recently in a study with hypertensive and normo-
tensive type 2 diabetic patients, ramipril versus placebo sive therapy. As noted, no differential effects on the
progression of neuropathy were observed in the presentdemonstrated an advantage with regard to the progres-
sion to overt albuminuria as measured as determined by study between intensive and moderate blood pressure
therapy, or between the initial therapy with a CCB andurinary albumin/creatinine ratios [8]. Other studies in
type 2 diabetic patients have demonstrated an advantage ACE inhibitor.
The beneficial effects of intensive blood pressure con-of ACE inhibitors on albuminuria when compared to
calcium channel blockers (CCBs) or beta-blockers but trol in the current study were not restricted to microvas-
cular complications of retinopathy and albuminuria. Athese studies had a relatively short follow-up of two
years or less and blood pressure was not as aggressively significant decrease in the occurrence of strokes also was
observed with intensive blood pressure control (P lowered as in the present intensive treatment group
[36, 37]. It may be, therefore, that at well-controlled 0.03). These results are similar to studies examining the
effects of isolated systolic blood pressure control in el-levels of blood pressure (130/80 mm Hg) any advantage
of ACE inhibitors on albuminuria may be difficult to derly hypertensive diabetic subjects wherein the use of
either a diuretic or calcium channel blocker based antihy-demonstrate.
Another significant and clinically important observa- pertensive resulted in a decreased incidence of strokes
[6, 9, 10]. In the present normotensive ABCD study,tion in this normotensive ABCD study related to the
progression of diabetic retinopathy. Earlier studies have a significantly lower systolic as well as diastolic blood
pressure was present in the intensive as compared to thesuggested that there is a positive correlation between
hypertension and the incidence or progression of dia- moderate therapy group.
No difference in non-stroke cardiovascular events be-betic retinopathy [38–40]. Although in the present study
there was no difference with regard to the development tween intensive versus moderate therapy were detected
in this normotensive ABCD study. There was also no dif-of retinopathy or proliferative retinopathy, we demon-
strated a benefit in the intensive blood pressure group ference between the incidence of cardiovascular events
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